Long-term use of antiretroviral therapy (ART) for HIV infection might lead to the necessity of switching regimens. We aimed to analyze the reasons for the ART switch, the time-to-switch of ART, and its associated factors in a Colombian cohort.
Methods
We conducted a retrospective cohort in 20 HIV clinics, including participants ≥18 years old with confirmed HIV infection who underwent an ART switch from January 2017 to December 2019 with at least 6 months of follow-up. A time-to-event analysis and an exploratory Cox model were performed.
Results
796 participants switched ART during the study period. The leading cause of ART switch was drug intolerance (n = 449; 56.4%) with a median time-to-switch of 12.2 months. The longest median time-to-switch was due to regimen simplification (42.4 months). People ≥50 years old (HR = 0.6; 95% CI (0.5–0.7) and CDC stage 3 at diagnosis (HR = 0.8; 95% CI (0.6–0.9) had less hazard for switching ART over time.
Conclusions
In this Colombian cohort, drug intolerance was the main cause of the ART switch, and the time-to-switch is shorter than reports from other countries. In Colombia, it is crucial to apply current recommendations for ART initiation to choose regimens with a better tolerability profile.
KirtaneARLangerRTraversoG. Past, present, and future drug delivery systems for antiretrovirals. J Pharm Sci2016; 105(12): 3471–3482.
2.
Meir-ShafrirKPollackS. Accelerated aging in HIV patients. Rambam Maimonides Med J2012; 3(4): e0025.
3.
FontelaCCastillaJJuanbeltzR, et al.Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016. Postgrad Med2018; 130: 317–324.
4.
KelesidisTCurrierJS. Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection. Endocrinol Metab Clin North Am2014; 43(3): 665–684.
5.
AzevedoLNXimenesRAAMonteiroP, et al.Factors associated to modification of first-line antiretroviral therapy due to adverse events in people living with HIV/AIDS. Braz J Infect Dis2020; 24(1): 65–72.
6.
NolanDReissPMallalS. Adverse effects of antiretroviral therapy for HIV infection: A review of selected topics. Expert Opin Drug Saf2005; 4(2): 201–218.
7.
CarrACooperDA. Adverse effects of antiretroviral therapy. Lancet2000; 356(9239): 1423–1430.
8.
RamadhaniHOThielmanNMLandmanKZ, et al.Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among hiv-infected adults receiving antiretroviral therapy in tanzania. Clin Infect Dis2007; 45(11): 1492–1498.
9.
MadecYLeroySRey-CuilleMA, et al.Persistent difficulties in switching to second-line ART in sub-saharan Africa--a systematic review and meta-analysis. PLoS ONE2013; 8(12): e82724.
10.
CohenC. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen. HIV Clin Trials2009; 10(2): 116–124.
11.
Martínez-CajasJLMueses-MarínHFGalindo-OrregoP, et al.Resistencia a drogas antirretrovirales en pacientes expuestos a terapia antirretroviral en Cali, Colombia, 2008-2010. Biomédica. 2013;33(4).
12.
HumphreysEHHernandezLBRutherfordGW. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev2010 Jun 16; 16: CD006517. doi: 10.1002/14651858.CD006517.pub3. PMID:20556768.
13.
HamersRLSigaloffKCEWensingAM, et al.Patterns of HIV-1 drug resistance after first-line Antiretroviral Therapy (ART) failure in 6 Sub-Saharan African Countries: implications for second-line ART Strategies. Clin Infect Dis2012; 54(11): 1660–1669.
14.
Ministerio de Salud y Protección Social, Empresa Nacional Promotora del Desarrollo Territorial e Instituto de Evaluación Tecnológica en Salud. Guía de práctica clínica (GPC) basada en la evidencia científica para la atención de la infección por VIH/Sida en adolescentes (con 13 años de edad o más) y adultos. Versión para profesionales de salud [Internet]. 1ra edicion. Ministerio de Salud Y Protección Social: Bogotá, Colombia; 2014. 46–47 p. Available at: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/CA/gpc-completa-evidencia-cientifica-vih-sida-adolescentes-adultos.pdf
Ministerio de Salud y Protección Social, Empresa Nacional Promotora del Desarrollo Territorial e Instituto de Evaluación Tecnológica en Salud. Guía de Práctica Clínica (GPC) basada en la evidencia científica para la atención de la infección por VIH/SIDA en personas adultas, gestantes y adolescentes. Bogota, Colombia: Ministerio de Salud Y Protección Social. Versión para profesionales de salud. 2da edición; 2021. 1544 p. Available at: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/PP/ET/gpc-vih-adultos-version-profesionales-salud.pdf
AlvarezLSSalmonJWSwartzmanD. The Colombian health insurance system and its effect on access to health care. Int J Health Serv2011; 41(2): 355–370.
19.
ArnettDKBlumenthalRSAlbertMA, et al.2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol2019; 74(11): 1376–1414.
20.
HawkinsCAchenbachCFrydaW, et al.Antiretroviral durability and tolerability in hiv-infected adults living in urban Kenya. J Acquir Immune Defic Syndr2007; 45(3): 304–310.
21.
Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Washington, DC, USA: Department of Health and Human Services. Available athttps://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv (Accessed Apr 18).
22.
PeterPCOncatoJKemperEl, et al.A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol1996; 49(12): 1373–1379.
Gómez HernándezAJMedina VasquezLMMolina CastañoCF, et al.. Efecto del cambio de la terapia antirretroviral en la falla virológica en una cohorte de pacientes que conviven con el VIH en Medellín, Antioquia, Colombia. Archivos de Medicina (Manizales)2020; 20(2): 269–281.
25.
KabarambiABalindaSAbaasaA, et al.Determinants and reasons for switching anti-retroviral regimen among HIV-infected youth in a large township of South Africa. Durham, NC. USA2021. Available at:https://www.researchsquare.com/article/rs-942036/v1
26.
Arévalo-MoraLMoscosoSAcostaA, et al.Complejidad de la transición de los esquemas antirretrovirales en un programa de atención de VIH en Bogotá durante el periodo de 2015-2017. Bogotá, Colombia: National University of Colombia. Available at:https://revistas.unal.edu.co/index.php/rccquifa/article/view/84954
MessouEAnglaretXDuvignacJ, et al.Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy. AIDS2010; 24(1): 93–99.
29.
HartECurtisHWilkinsE, et al.National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients. HIV Med2007; 8(3): 186–191.
30.
CesarCShepherdBEKrolewieckiAJ, et al.Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS ONE2010; 5(6): e10510–104900.
31.
SoorjuVNaidooPHospitalM.Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a regional hospital in rural KwaZulu-Natal. Afr J Prim Health Care Fam Med2016; 8(1): e1–e6.
32.
RuzickaDJKuroishiNOshimaN, et al.Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database. BMC Infect Dis2019; 19: 505–511.
33.
HaasADKeiserOBalestreE, et al.Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. Lancet HIV2016; 2(7): e271–e278.
34.
NjugunaCOrrellCKaplanR, et al.Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS ONE2013; 8(5): e63596–e63597.
35.
Ministerio de Salud y Protección social. Plan Nacional de respuesta ante las ITS, el VIH, la coinfección TB/VIH y las Hepatitis B Y C, Colombia 2018-2021. Bogota, Colombia: Ministerio de Salud Y Protección Social, 2018.
36.
Group TAL ofISKeiserOTweyaH, et al.Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS, Bern, Switzerland2009; 23: 1867–1874.
37.
DesmondeSEbouaKMalatesteF, et al.Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation. AIDS2015; 29(12): 1527–1536.
38.
GlickJLHuangARussoRJivapongBRamasamyVRosmanLPelaezDFooterKHAShermanSG.ART uptake and adherence among women who use drugs globally: A scoping review. Drug Alcohol Depend2020 Oct 1 215:108218. Epub 2020 Aug 2. PMID: 32916450; PMCID: PMC7899784. doi: 10.1016/j.drugalcdep.2020.108218.
39.
SarfoFSSarfoMAChadwickD. Incidence and risk factors for neuropsychiatric events among Ghanaian HIV patients on long-term non-nucleoside reverse transcriptase inhibitor-based therapy. eNeurologicalSci2016; 3: 21–25.
40.
KirsteinLMGreenblattRMAnastosA, et al.Prevalence and correlates of highly active antiretroviral therapy switching in the women’s interagency HIV Study. J Acquir Immune Defic Syndr2002; 29: 495–503.
41.
Bell-GorrodHFoxMPBoulleA, et al.The impact of delayed switch to second-line antiretroviral therapy on mortality, depending on definition of failure time and cd4 count at failure. Am J Epidemiol2020; 189(8): 811–819.
42.
ZhengCMengJXiaoX, et al.Polypharmacy, medication-related burden and antiretroviral therapy adherence in people living with HIV aged 50 and above: a cross-sectional study in hunan, China. Patient Prefer Adherence2022; 16: 41–49.
43.
GhideiLSimoneMJSalowMJ, et al.Aging, antiretrovirals, and adherence: a meta analysis of adherence among older hiv-infected individuals. Drugs Aging2013; 30(10): 809–819.
44.
Cuenta de Alto Costo. SITUACIÓN DEL VIH y sida en Colombia 2021. Bogotá, Colombia, 2022.
45.
PalombiLMarazziMCGuidottiG, et al.Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis2009; 48(1): 115–122.
46.
VanobberghenFMKilamaBWringeA, et al.Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data. Trop Med Int Health2015; 20(7): 880–892.
47.
RossJJiamsakulAKumarasamyN, et al.Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific. HIV Med2021; 22(3): 201–211.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
